{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:01:07Z","timestamp":1787580067687,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T00:00:00Z","timestamp":1420675200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00277-014-2290-y","type":"journal-article","created":{"date-parts":[[2015,1,7]],"date-time":"2015-01-07T00:48:39Z","timestamp":1420591719000},"page":"1017-1024","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Quality of life in multiple myeloma: clinical validation of the Mexican-Spanish version of the QLQ-MY20 instrument"],"prefix":"10.1007","volume":"94","author":[{"given":"Jos\u00e9 Ramiro","family":"Espinoza-Zamora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar Miguel","family":"Portilla-Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Rafael","family":"Labardini-M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Niesvisky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"O\u00f1ate-Oca\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,8]]},"reference":[{"issue":"9686","key":"2290_CR1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","volume":"374","author":"MS Raab","year":"2009","unstructured":"Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC (2009) Multiple myeloma. Lancet 374(9686):324\u2013339. doi: 10.1016\/S0140-6736(09)60221-X","journal-title":"Lancet"},{"key":"2290_CR2","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer. http:\/\/globocan.iarc.fr . Accessed 5 Nov 2013"},{"key":"2290_CR3","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473","journal-title":"Leukemia"},{"key":"2290_CR4","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D, Apperley J, Bj\u00f6rkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115\u20131123","journal-title":"Br J Haematol"},{"key":"2290_CR5","doi-asserted-by":"crossref","unstructured":"Fayers PM, Machin D (eds) (2007) Quality of life: the assessment, analysis, and interpretation of patient-reported outcomes. 2nd ed. Wiley, West Sussex, UK","DOI":"10.1002\/9780470024522"},{"key":"2290_CR6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"2290_CR7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","volume":"1","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K (2003) The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1:79","journal-title":"Health Qual Life Outcomes"},{"key":"2290_CR8","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","volume":"43","author":"Cocks K, Cohen D, Wisl\u00f8ff F, Sezer O, Lee S, Hippe E, Gimsing P, Turesson I, Hajek R, Smith A, Graham L, Phillips A, Stead M, Velikova G, Brown J; EORTC Quality of Life Group","year":"2007","unstructured":"Cocks K, Cohen D, Wisl\u00f8ff F, Sezer O, Lee S, Hippe E, Gimsing P, Turesson I, Hajek R, Smith A, Graham L, Phillips A, Stead M, Velikova G, Brown J; EORTC Quality of Life Group (2007) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 43:1670\u20131678","journal-title":"Eur J Cancer"},{"key":"2290_CR9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-8722-6-13","volume":"6","author":"D Jones","year":"2013","unstructured":"Jones D, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK, Johnson VE, Champlin RE, Cleeland CS, Mendoza TR (2013) Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol 6:13. doi: 10.1186\/1756-8722-6-13","journal-title":"J Hematol Oncol"},{"key":"2290_CR10","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3109\/10428194.2012.662643","volume":"53","author":"A Alegre","year":"2012","unstructured":"Alegre A, Oriol-Rocafiguera A, Garc\u00eda-Lara\u00f1a J, Mateos MV, Sureda A, Mart\u00ednez-Chamorro C, Cibeira MT, Aguado B, Knight R, Rosettani B (2012) Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. Leuk Lymphoma 53:1714\u20131721","journal-title":"Leuk Lymphoma"},{"key":"2290_CR11","unstructured":"National Comprehensive Cancer Network (2011) Clinical practice guidelines in oncology: Waldenstr\u00f6m\u2019s macroglobulinemia\/lymphoplasmacytic lymphoma. v2.2011. http:\/\/www.nccn.org . Accessed 24 Aug 2013"},{"key":"2290_CR12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group","year":"2003","unstructured":"International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749\u2013757","journal-title":"Br J Haematol"},{"key":"2290_CR13","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1373\/clinchem.2008.106153","volume":"54","author":"AP Piehler","year":"2008","unstructured":"Piehler AP, Gulbrandsen N, Kierulf P, Urdal P (2008) Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population. Clin Chem 54:1823\u20131830","journal-title":"Clin Chem"},{"key":"2290_CR14","first-page":"1329","volume-title":"Bone and joint imaging","author":"D Resnick","year":"1996","unstructured":"Resnick D (1996) In: Bralow L (ed) Bone and joint imaging. WB Saunders, Philadelphia, PA, USA, p 1329"},{"key":"2290_CR15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/02841850500215360","volume":"46","author":"ME Mulligan","year":"2005","unstructured":"Mulligan ME (2005) Imaging techniques used in the diagnosis, staging, and follow-up of patients with myeloma. Acta Radiol 46:716\u2013724","journal-title":"Acta Radiol"},{"key":"2290_CR16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","volume":"367","author":"A Palumbo","year":"2006","unstructured":"Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:825\u2013831","journal-title":"Lancet"},{"key":"2290_CR17","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1080\/10428190701647887","volume":"48","author":"R Niesvizky","year":"2007","unstructured":"Niesvizky R, Mart\u00ednez-Ba\u00f1os D, Jalbrzikowski J, Christos P, Furst J, De Sancho M, Mark T, Pearse R, Mazumdar M, Zafar F, Pekle K, Leonard J, Jayabalan D, Coleman M (2007) Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 48:2330\u20132337","journal-title":"Leuk Lymphoma"},{"key":"2290_CR18","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","volume":"28","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Rossi D et al (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 28:5101\u20135109","journal-title":"J Clin Oncol"},{"key":"2290_CR19","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Schlossman RL, Weller E et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063\u20133067","journal-title":"Blood"},{"key":"2290_CR20","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/JCO.2006.05.6689","volume":"24","author":"L Mileshkin","year":"2006","unstructured":"Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24:4507\u20134514","journal-title":"J Clin Oncol"},{"key":"2290_CR21","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","volume":"114","author":"S Kumar","year":"2009","unstructured":"Kumar S, Giralt S, Stadtmauer EA et al (2009) Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide or bortezomib-containing regimens. Blood 114:1729\u20131735","journal-title":"Blood"},{"key":"2290_CR22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1245\/s10434-008-0175-9","volume":"16","author":"LF O\u00f1ate-Oca\u00f1a","year":"2009","unstructured":"O\u00f1ate-Oca\u00f1a LF, Alc\u00e1ntara-Pilar A, Vilar-Compte D, Garc\u00eda-Hubard G, Rojas-Castillo E, Alvarado-Aguilar S, Carrillo JF, Blazeby JM, Aiello-Crocifoglio V (2009) Validation of the Mexican Spanish version of the EORTC C30 and STO22 questionnaires for the evaluation of health-related quality of life in patients with gastric cancer. Ann Surg Oncol 16:88\u201395","journal-title":"Ann Surg Oncol"},{"key":"2290_CR23","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.ejca.2007.05.029","volume":"43","author":"Koller M, Aaronson NK, Blazeby J, Bottomley A, Dewolf L, Fayers P, Johnson C, Ramage J, Scott N, West K; EORTC Quality of Life Group","year":"2007","unstructured":"Koller M, Aaronson NK, Blazeby J, Bottomley A, Dewolf L, Fayers P, Johnson C, Ramage J, Scott N, West K; EORTC Quality of Life Group (2007) Translation procedures for standardized quality of life questionnaires: the European Organisation for Research and Treatment of Cancer (EORTC) approach. Eur J Cancer 43:1810\u20131820","journal-title":"Eur J Cancer"},{"key":"2290_CR24","volume-title":"The EORTC QLQ-C30 scoring manual","author":"PM Fayers","year":"2001","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels, Belgium","edition":"3"},{"key":"2290_CR25","volume-title":"Using multivariate statistics","author":"BG Tabachnick","year":"2012","unstructured":"Tabachnick BG, Fidell LS (2012) Using multivariate statistics, 6th edn. Pearson, New York, NY, USA","edition":"6"},{"key":"2290_CR26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ejh.12012","volume":"89","author":"TR Osborne","year":"2012","unstructured":"Osborne TR, Ramsenthaler C, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ (2012) What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools. Eur J Haematol 89:437\u2013457. doi: 10.1111\/ejh.12012","journal-title":"Eur J Haematol"},{"key":"2290_CR27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1600-0609.2009.01303.x","volume":"83","author":"AK Kvam","year":"2011","unstructured":"Kvam AK, Fayers P, Hjermstad M, Gulbrandsen N, Wisloff F (2011) Health-related quality of life assessment in randomized controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur J Haematol 83:279\u2013289. doi: 10.1111\/j.1600-0609.2009.01303.x","journal-title":"Eur J Haematol"},{"key":"2290_CR28","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/leu.2013.185","volume":"27","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld P, Verelst SG, Lewis P, Gray-Schopfer V, Hutchings A, Nixon A, Petrucci MT (2013) Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia 27:1959\u20131969. doi: 10.1038\/leu.2013.185","journal-title":"Leukemia"},{"key":"2290_CR29","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1100\/2012\/842867","volume":"2012","author":"N Kontodimopoulos","year":"2012","unstructured":"Kontodimopoulos N, Samartzis A, Papadopoulos AA, Niakas D (2012) Reliability and validity of the Greek QLQ-C30 and QLQ-MY20 for measuring quality of life in patients with multiple myeloma. Sci World J 2012:842\u2013867. doi: 10.1100\/2012\/842867","journal-title":"Sci World J"},{"key":"2290_CR30","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1600-0609.2011.01665.x","volume":"87","author":"AK Kvam","year":"2011","unstructured":"Kvam AK, Fayers PM, Wisloff F (2011) Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. Eur J Haematol 87:330\u2013337. doi: 10.1111\/j.1600-0609.2011.01665.x","journal-title":"Eur J Haematol"},{"key":"2290_CR31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1600-0609.2009.01404.x","volume":"84","author":"AK Kvam","year":"2010","unstructured":"Kvam AK, Fayers P, Wisloff F (2010) What changes in health-related quality of life matter to multiple myeloma patients? A prospective study. Eur J Haematol 84:345\u2013353. doi: 10.1111\/j.1600-0609.2009.01404.x","journal-title":"Eur J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2290-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-014-2290-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2290-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:49:56Z","timestamp":1559036996000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-014-2290-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,8]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["2290"],"URL":"https:\/\/doi.org\/10.1007\/s00277-014-2290-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,8]]}}}